Oral Omega-3 Fatty Acids in the Treatment of Dry Eye Syndrome
Status:
Completed
Trial end date:
2015-06-15
Target enrollment:
Participant gender:
Summary
The investigators hypothesize that oral omega-3-acid ethyl esters (Lovaza, GlaxoSmithKline,
Research Triangle Park, NC) will decrease dry-eye related symptoms as well as clinical
markers associated with dry eye disease (Schirmer-1 test values, positive vital staining with
lissamine green, and fluorescein tear break-up time) when compared to administration of
placebo.
Phase:
N/A
Details
Lead Sponsor:
Milton S. Hershey Medical Center
Collaborators:
GlaxoSmithKline The American Society of Cataract and Refractive Surgery Foundation